V
46
-2
LRCX
48
-2
STI
4
-2
PM
58
-2
PEP
38
-12
R
61
2
KO
49
-16
CMS
55
-3
PSA
50
-5
RHI
23
-2
CA
19
-3
EXR
40
-6
JCI
54
3
GM
65
15
MS
53
-9
TSCO
50
5
CHRW
67
3
TMO
46
2
DE
58
9
BA
47
4
V
46
-2
LRCX
48
-2
STI
4
-2
PM
58
-2
PEP
38
-12
R
61
2
KO
49
-16
CMS
55
-3
PSA
50
-5
RHI
23
-2
CA
19
-3
EXR
40
-6
JCI
54
3
GM
65
15
MS
53
-9
TSCO
50
5
CHRW
67
3
TMO
46
2
DE
58
9
BA
47
4
Financhill
Back

Arcturus Therapeutics Holdings Stock Predictions

Apple just traded your privacy for $20 Billion

This is a paid advertisement for Mode Mobile Regulation A offering. Please read the offering circular and related risks at invest.modemobile.com.
Sell
21

ARCT
Arcturus Therapeutics Holdings

Last Price:
$12.88
Seasonality Move:
23.59%

7 Day Trial

ALL ACCESS PASS

$ 7

Meet the Founder That's Revolutionizing Smartphones

This is a paid advertisement for Mode Mobile Regulation A offering. Please read the offering circular and related risks at invest.modemobile.com.

Arcturus Therapeutics Holdings Stock Forecast

  • Over the next 52 weeks, Arcturus Therapeutics Holdings has on average historically risen by 14.2% based on the past 11 years of stock performance.
  • Arcturus Therapeutics Holdings has risen higher in 3 of those 11 years over the subsequent 52-week period, corresponding to a historical accuracy of 27.27%
  • Is Arcturus Therapeutics Holdings Stock Undervalued?
    The current Arcturus Therapeutics Holdings [ARCT] share price is $12.88. The Score for ARCT is 21, which is 58% below its historic median score of 50, and infers higher risk than normal.
  • ARCT is currently trading in the 20-30% percentile range relative to its historical Stock Score levels.

Will Arcturus Therapeutics Holdings Stock Go Up Next Year?

  • Over the next 52 weeks, Arcturus Therapeutics Holdings has on average historically risen by 14.2% based on the past 11 years of stock performance.

Arcturus Therapeutics Holdings Stock Rating

Sell
21
Arcturus Therapeutics Holdings (ARCT) is a Sell

Is Arcturus Therapeutics Holdings overpriced?

  • Arcturus Therapeutics Holdings has risen higher in 3 of those 11 years over the subsequent 52-week period, corresponding to a historical accuracy of 27.27%

Arcturus Therapeutics Holdings Stock Price History

Is ARCT stock going to rise?

  • Based on the share price being below its 5, 20 & 50 day exponential moving averages, the current trend is considered strongly bearish and ARCT is experiencing buying pressure, which is a positive indicator for future bullish movement.

Stock Information

Stock Info

Exchange:
NASDAQ
Country:
United States
Industry:
Biotechnology
Sector:
Health Care
Type:
stock
Website:
arcturusrx.com

52-Week Data

52-Week High:
45.00
52-Week Low:
11.60

Prediction Charts

Market Cap:
349.3M
Price in USD:
12.88
Volume:
559.3K
Beta:
2.51

Technical Analysis

SMA50:
16.29
SMA100:
16.99
SMA200:
20.37
52-Wk Change:
-61.12%

Stock Predictions

  • Is Arcturus Therapeutics Holdings stock public?
    Yes, Arcturus Therapeutics Holdings is a publicly traded company.
  • What is the Arcturus Therapeutics Holdings stock quote today?
    The Arcturus Therapeutics Holdings stock price is 12.88 USD today.
  • How to buy Arcturus Therapeutics Holdings stock online?
    You can buy Arcturus Therapeutics Holdings shares by opening an account at a top tier brokerage firm, such as TD Ameritrade or tastyworks.

14-Day Historical Data

Date Opening Closing Minimum Maximum
Mar-3 17.08 15.68 17.32 15.43
Mar-4 15.29 15.49 15.95 14.69
Mar-5 15.61 16.05 16.21 15.45
Mar-6 15.79 15.97 16.18 15.49
Mar-7 14.80 14.55 15.40 14.11
Mar-11 14.42 13.21 14.78 12.75
Mar-12 13.54 14.26 14.50 13.39
Mar-13 14.15 13.90 14.56 13.57
Mar-14 14.02 14.08 14.29 13.38
Mar-17 14.08 14.16 14.56 13.81
Mar-18 13.92 13.73 14.37 13.39
Mar-19 13.76 13.40 13.88 13.18
Mar-20 13.22 12.84 13.54 12.65
Mar-21 12.59 12.88 12.93 11.60

Arcturus Therapeutics Holdings Earnings

Arcturus Therapeutics Holdings Earnings Report: Per Share Arcturus Therapeutics Holdings Earnings Q1 Q2 Q3 and Q4 last year and next year.

Arcturus Therapeutics Holdings Forecast Revenue Growth

Arcturus Therapeutics Holdings Stock Analysis: Historical quarterly revenues per share for Arcturus Therapeutics Holdings and historical quarterly revenue growth:

  • Analysts estimate an earnings decrease this quarter of $0.20 per share, a decrease next quarter of $0.14 per share, a decrease this year of $2.40 per share, and an increase next year of $0.98 per share.

* Arcturus Therapeutics Holdings stock forecasts short-term for next days and weeks may differ from long term prediction for next month and year based on timeline differences.